Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species

Journal of Neurochemistry

Volumn 71, Issue 5, 1998, Pages 2112-2122

  Spencer, Jeremy P E ^a   Jenner, Peter ^a   Daniel, Susan E ^b   Lees, Andrew J ^b   Marsden, David C ^b   Halliwell, Barry ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

5 S Cysteinyldopamine; 5 S Cysteinyl 3,4 dihydroxyphenylalanine; L 3,4 Dihydroxyphenylalanine; Oxidative stress; Parkinson's disease; Superoxide; Lipoate

Indexed keywords

DOPA; GLUTATHIONE; LEVODOPA;

ARTICLE; DOPAMINE METABOLISM; GLUTATHIONE METABOLISM; HUMAN; HUMAN TISSUE; NERVE CELL NECROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0031722906     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71052112.x     Document Type: Article

References (49)

1. Agrup G., Edholm L.-E., Rorsman H., and Rosengren E. (1983) Diastereomers of 5-S-cysteinyldopa. Acta Derm. (Stockh.) 63, 59-61.
2. Anden N.-E., Fuxe K., Hamberger B., and Hokfelt T. (1966) A quantitative study on the nigroneostriatal dopamine neuron system in the rat. Acta Physiol. Scand. 67, 306-312.
3. Aruoma O. I., Halliwell B., and Dizdaroglu M. (1989) Iron ion-dependent modification of bases in DNA by the superoxide radical-generating system hypoxanthine/xanthine oxidase. J. Biol. Chem. 264, 13024-13028.
4. •- radicals in aqueous solution. J. Phys. Chem. Ref. Data 14, 1041-1100.
5. Bindoli A., Rigobello M. P., and Deeble D. J. (1992) Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol Med. 13, 391-405.
6. Busse E., Zimmer G., Schopohl B., and Kornhuber B. (1992) Influence of α-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforschung/Drug Res. 42, 829-831.
7. Carstam R., Brinck C., Hindemith-Augustsson A., Rorsman H., and Rosengren E. (1991) The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
8. Cheng F.-C., Kuo J.-S., and Dryhurst G. (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J. Neural Transm. 103, 433-446.
9. Cohen G. (1983) The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence. J. Neural Transm. Suppl. 19, 89-103.
10. Cohen G. (1986) Monoamine oxidase, hydrogen peroxide and Parkinson's disease. Adv. Neurol. 45, 119-125.
11. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in the brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
12. Dexter D. T., Carayon A., Javoy-Agid F., Agid Y., Wells F. R., Daniel S. E., Lees A. J., Jenner P., and Marsden C. D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114, 1953-1975.
13. Dexter D. T., Jenner P., Schapira A. H. V., and Marsden C. D. (1992) Alterations in the levels of iron, ferritin and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann. Neurol. 32, S94-S100.
14. Ellman G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70-77.
15. Fornstedt B. and Carlsson A. (1991) Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in the guinea pig striatum. J. Neurochem. 56, 407-414.
16. Fornstedt B., Rosengren E., and Carlsson A. (1986) Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25, 451-454.
17. Fornstedt B., Brun A., Rosengren E., and Carlsson A. (1989) The apparent autooxidation rate of catechols in dopamine-rich regions of human brains increases with the degree of depigmentation of substantia nigra. J. Neural Transm. 1, 279-295.
18. Fornstedt B., Bergh I., Rosengren E., and Carlsson A. (1990) An improved HPLC-electrochemical detection method of measuring brain levels of 5-S-cysteinyldopamine, 5-S-cysteinyl-3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylacetic acid. J. Neurochem. 54, 578-586.
19. Gotz M. E., Kunig G., Riederer P., and Youdim M. B. H. (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol. Ther. 63, 37-122.
20. Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
21. Halliwell B. (1992) Reactive oxygen species and the central nervous system. J. Neurochem. 59, 1609-1623.
22. Halliwell B. and Gutteridge J. M. C. (1989) Free Radicals in Biology and Medicine, 2nd edit. Clarendon Press, Oxford.
23. Jenner P. (1994) Oxidative damage in neurodegenerative disease. Lancet 344, 796-798.
24. Jenner P., Dexter D. T., Sian J., Schapira A. H. V., and Marsden C. D. (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32, S82-S87.
25. Kish S. J., Morito C., and Hornykiewicz O. (1986) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346.
26. Li H. and Dryhurst G. (1997) Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
27. Muller U. and Krieglstein J. (1995) Prolonged pre-treatment with α-lipoic acid protects cultured neurons against hypoxic, glutamate-, or iron-induced injury. J. Cereb. Blood Flow Metab. 15, 624-630.
28. Odh G., Carstam R., Paulson J., Wittbjer A., Rosengren E., and Rorsman H. (1994) Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62, 2030-2036.
29. Packer L., Witt E. H., and Tritschler H. J. (1995) Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 19, 227-250.
30. Packer L., Tritschler H. J., and Wessel K. (1997) Neuroprotection by the metabolic antioxidant a-lipoic acid. Free Radic. Biol. Med. 22, 359-378.
31. Palumbo A., d'Ischia M., Misuraca G., De Martino L., and Prota G. (1995) Iron-and peroxide-dependent conjugation of dopamine with cysteine: oxidative routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta 1245, 255-261.
32. Perry T. L., Godin D. A., and Hansen S. (1982) Parkinson's disease: a disorder due to glutathione deficiency? Neurosci. Lett. 33, 305-310.
33. Ploemen J. H. T. M., Van Ommen B., De Haan A., Venekamp J. C., and Van Bladeren P. J. (1994) Inhibition of human glutathione-S-transferases by dopamine, α-methyldopa and their 5-S-glutathionyl conjugates. Chem. Biol. Interact. 90, 87-99.
34. Riederer P., Sofic E., Rausch W.-D., Schmidt B., Reynolds G. P., Jellinger K., and Youdim M. B. H. (1989) Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J. Neurochem. 52, 515-520.
35. Riederer P., Dirr A., Goetz M., Sofic E., and Youdim M. B. H. (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann. Neurol. 32, S101-S104.
36. Rosengren E., Linder-Eliasson E., and Carlsson A. (1985) Detection of 5-S-cysteinyldopamine in human brain. J. Neural Transm. 63, 247-253.
37. Scott B. C., Aruoma O. I., Evans P. J., O'Neill C., Van Der Vliet A., Cross C. E., Tritschler H,. and Halliwell B. (1994) Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Free Radic. Res. 20, 119-133.
38. 14C-deoxyglucose incorporation in rat basal ganglia. Biochem. Pharmacol. 51, 983-986.
39. Shen X.-M. and Dryhurst G. (1996) Further insights into the influence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's disease. Chem. Res. Toxicol. 9, 751-763.
40. Shen X.-M., Zhang F., and Dryhurst G. (1997) Oxidation of dopamine in the presence of cysteine: characterisation of new toxic products. Chem. Res. Toxicol. 10, 147-155.
41. Sian J., Dexter D. T., Jenner P., and Marsden C. D. (1992) Glutathione related enzymes in brain in basal ganglia degenerative disorders. Br. J. Pharmacol. 107 (Suppl.), 428P.
42. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., and Marsden C. D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting the basal ganglia. Ann. Neurol. 36, 348-355.
43. Spencer J. P. E., Jenner P., and Halliwell B. (1995) Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. Neuroreport 6, 1480-1484.
44. Spina M. B. and Cohen G. (1988) Exposure of school synaptosomes to L-DOPA increases levels of oxidized glutathione. J. Pharmacol. Exp. Ther. 247, 502-507.
45. Winterbourn C. C. and Metodiewa D. (1994) The reaction of superoxide with reduced glutathione. Arch. Biochem. Biophys. 314, 284-290.
46. Zhang F. and Dryhurst G. (1993) Oxidation chemistry of dopamine. Possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 21, 392-410.
47. Zhang F. and Dryhurst G. (1993) Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J. Med. Chem. 37, 1084-1098.
48. Zhang F. and Dryhurst G. (1995a) Influence of glutathione on the oxidation chemistry of the catecholaminergic neurotransmitter dopamine. J. Electroanal. Chem. 398, 117-128.
49. Zhang F. and Dryhurst G. (1995b) Reactions of cysteine and cysteinyl derivatives with dopamine-o-quinone and further insights into the oxidation chemistry of 5-S-cysteinyldopamine: potential relevance to idiopathic Parkinson's disease. Bioorg. Chem. 23, 193-216.